Rejuvenation Technologies Inc.: mRNA therapeutics to extend healthspan entering clinical trials | Y Combinator
Summary
Rejuvenation Technologies is raising a $10M seed extension, with more than $2M already wired. The company is taking its mRNA therapeutics platform into clinical trials to extend healthspan by addressing telomere shortening. It says the platform has shown preclinical effects across four organ systems and has FDA INTERACT clearance. The company also highlights a large patent portfolio and plans to use the proceeds to fund three investigator-initiated trials, with readouts expected in Q3 2027.
Funding
Amount
-
Total raised
Date
August 22, 2018
Announcement date
Investors
Y Combinator
Lead investors
Company
https://www.rejuvenationtech.com/
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected